Clinical research continues to struggle with a lack of representation within trial populations, and gender diversity in clinical trials remains a critical issue.
When Emma Walmsley took the reins of GlaxoSmithKline (GSK) in 2016, becoming the first woman to head up a major pharmaceutical company, it was headline news.
Novartis has struck another deal to build its position in radiopharmaceuticals, agreeing to pay $1 billion upfront for radioligand therapy (RLT) developer Mariana Oncology
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.